In postmenopausal tumours, HER2 was elevated in 19 of 22 (individual ratio: 2.48; CI: 1.70-3.65, P<0.001) and HER3 in 21 out of 22 (individual ratio: 22.27; CI: 9.03-54.92, P<0.001). This evidence concerns the gene ERBB2 and neoplasm.